Testing a new drug for advanced bladder cancer
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial is for people with advanced bladder cancer (urothelial cancer) that has spread or can't be removed. It tests a new drug called sacituzumab tirumotecan against standard chemotherapy options to see if it works better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced bladder cancer that has spread or can't be fully removed by surgery.
- You've already had treatment with an immunotherapy drug (like Keytruda or Tecentriq), platinum chemotherapy, and another targeted drug called enfortumab vedotin (Padcev).
- You've had no more than 2 prior cancer treatments.
- Your cancer has gotten worse during or after your last treatment.
- You are well enough to take care of yourself (ECOG performance status 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares a new antibody-drug conjugate (sacituzumab tirumotecan) to other similar drugs for advanced bladder cancer that hasn't responded to prior treatment. It aims to see which is more effective and safe.
This trial tests a new combination of immunotherapy (tislelizumab) plus chemotherapy (cisplatin and gemcitabine) with or without an extra drug (trilaciclib) for people with advanced bladder cancer that hasn't been treated yet. The goal is to see if this combination is safe and helps shrink tumors.
This Phase 1/2 trial tests whether combining sacituzumab govitecan with enfortumab vedotin (and in one group, pembrolizumab) can shrink or control metastatic urothelial (bladder/urinary tract) cancer. It’s mainly for people whose cancer has grown despite prior treatment.
This trial is testing a combination of two drugs (disitamab vedotin and toripalimab) for people with muscle-invasive bladder cancer that has not spread. The goal is to see if this treatment can shrink the tumor before surgery. You may qualify if your tumor has a certain level of a protein called HER2.
This trial tests a new drug (sacituzumab tirumotecan) for people with rare types of kidney or bladder cancer that have spread. The drug targets a protein called TROP-2 on cancer cells. The goal is to see if it can shrink tumors or slow the cancer when other treatments have stopped working or are not available.
This trial tests a new drug called sacituzumab tirumotecan for people with low-grade bladder cancer that hasn't spread into the bladder muscle. The goal is to see if it can help shrink or control the tumors.
Hear when a new Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.